# Flonics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flonics-co

- Industry: Software
- Headquarters: Chuncheon-si, South Korea
- Website: www.flonics.co.kr/
- Total disclosed funding: $0.7M
- Latest round: Seed (Aug 26, 2025)
- Investors on record: 3

## About

Based in South Korea, FLONICS is a medical technology firm specializing in advanced imaging software for automated blood flow analysis, focusing on precise hemodynamic assessments for cardiovascular and cerebrovascular health.FLONICS, founded in 2024 in Chuncheon, South Korea, specializes in developing medical imaging software for blood flow analysis. The company has secured KRW 1 billion in Seed funding from investors including Kakao Ventures, Digital Healthcare Partners, and Kangwon National University Technology Holdings. The latest funding round concluded on August 26, 2025, bringing their total amount raised to KRW 1 billion. The founder's details are currently not available.FLONICS, Inc. specializes in the development of advanced medical imaging-based software solutions designed for automated blood flow analysis. The company’s core offerings include innovative software products that utilize cutting-edge 4D flow MRI technology to facilitate precise hemodynamic assessments for cardiovascular and cerebrovascular conditions. These solutions are particularly aimed at addressing critical health issues such as atherosclerosis, aortic aneurysms, and aortic dissection, providing clinicians with tools to enhance diagnostic accuracy, treatment planning, and patient management. The automated all-in-one solution streamlines the processes of imaging, analysis, and reporting, significantly improving efficiency in clinical workflows. FLONICS primarily serves hospitals, diagnostic imaging centers, and cardiovascular specialists across various international markets, including regions in North America and Europe.FLONICS generates revenue through the sale and licensing of its proprietary software products, including flagship solutions like MR-Cath and Virtual-Cath, which replace traditional invasive catheter pressure measurements with non-invasive methods. Transactions typically occur on a B2B basis, with healthcare institutions purchasing licenses for the software, potentially structured as annual subscriptions or one-time fees depending on the service agreement. Revenue may also be derived from partnerships and collaborations with medical device manufacturers and educational institutions, enhancing the reach and application of their technology in clinical settings. The company’s focus on innovative solutions positions it strategically within the evolving healthcare landscape, catering to a growing demand for advanced diagnostic tools in cardiovascular care.In August 2025, FLONICS raised KRW 1 billion in Seed funding to enhance its technology and complete its prototype. The company plans to expand its product line with new software solutions aimed at improving diagnostic capabilities, targeting release dates in the coming year. Additionally, FLONICS is looking to enter new markets in Europe and North America by the end of 2026, leveraging recent funding to support these expansion efforts.

## Funding rounds

- Seed, Aug 26, 2025, $0.7M — Kakao Ventures, Digital Healthcare Partners, Kangwon National University Technology Holdings

## Investors

- Kakao Ventures (https://capitalatlas.ai/funds/kakao-ventures) — Seed
- Digital Healthcare Partners (https://capitalatlas.ai/funds/digital-healthcare-partners) — Seed
- Kangwon National University Technology Holdings (https://capitalatlas.ai/funds/kangwon-national-university-technology-holdings) — Seed